US Food and Drug Administration (FDA) Approves Henlius and Organon’s BILDYOS® (denosumab-nxxp) and BILPREVDA® (denosumab-nxxp), Biosimilars to PROLIA (denosumab) and XGEVA (denosumab), Respectively - Candlesense
OGN Regulatory

US Food and Drug Administration (FDA) Approves Henlius and Organon’s BILDYOS® (denosumab-nxxp) and BILPREVDA® (denosumab-nxxp), Biosimilars to PROLIA (denosumab) and XGEVA (denosumab), Respectively

(NYSE:OGN) SHANGHAI & JERSEY CITY, N.J.--(BUSINESS WIRE)--FDA Approves Henlius and Organon’s BILDYOS® (denosumab-nxxp) and BILPREVDA® (denosumab-nxxp)

Related Questions

How will the FDA approval of BILDYOS® and BILPREVDA® affect Organon's near‑term stock price? What revisions to revenue and market‑share estimates for denosumab biosimilars are anticipated following the approval? How does the entry of these biosimilars impact competition with Amgen’s Prolia and XGEVA and the broader bone‑health market?
Find similar articles on Candlesense businesswire